| 1 |
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis
Paul D. Miller, Gary Hattersley, Bente Juel Riis et al. · JAMA
Open access |
16 Aug 2016 |
869 |
| 2 |
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
François‐Clément Bidard et al. · Journal of Clinical Oncology
Open access |
18 May 2022 |
754 |
| 3 |
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
Hitisha Patel, Teeru Bihani · Pharmacology & Therapeutics
Open access |
28 Dec 2017 |
525 |
| 4 |
Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling
Gary Hattersley, Thomas Roy Dean, Braden A. Corbin et al. · Endocrinology
Open access |
12 Nov 2015 |
303 |
| 5 |
Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis
Benjamin Z. Leder, Louis St L O'Dea, José Zanchetta et al. · The Journal of Clinical Endocrinology & Metabolism
|
13 Nov 2014 |
265 |
| 6 |
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
Dennis M. Black, Douglas C. Bauer, Eric Vittinghoff et al. · The Lancet Diabetes & Endocrinology
|
21 Jul 2020 |
236 |
| 7 |
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
Henry G. Bone, Felicia Cosman, Paul D. Miller et al. · The Journal of Clinical Endocrinology & Metabolism
Open access |
24 May 2018 |
208 |
| 8 |
Characteristics of recurrent fractures
John А. Kanis, H Johansson, A. Odén et al. · Osteoporosis International
Open access |
12 Jun 2018 |
188 |
| 9 |
Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge
Manuel Sánchez-Félix, Matt Burke, Hunter H. Chen et al. · Advanced Drug Delivery Reviews
ReviewOpen access |
27 May 2020 |
166 |
| 10 |
RAD1901
Fiona Garner, Maysoun Shomali, Dotty Paquin et al. · Anti-Cancer Drugs
Open access |
11 Jul 2015 |
165 |
| 11 |
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Teeru Bihani, Hitisha Patel, Heike Arlt et al. · Clinical Cancer Research
|
4 May 2017 |
164 |
| 12 |
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis
Felicia Cosman, Paul D. Miller, Gregory C. Williams et al. · Mayo Clinic Proceedings
Open access |
Feb 2017 |
130 |
| 13 |
Linking Physician Characteristics and Medicare Claims Data
Laura‐Mae Baldwin, Walter Adamache, Carrie N. Klabunde et al. · Medical Care
|
Aug 2002 |
126 |
| 14 |
Economic Burden of Osteoporosis-Related Fractures in the US Medicare Population
Setareh A. Williams, Shanette G. Daigle, RICHARD J. WEISS et al. · Annals of Pharmacotherapy
Open access |
4 Nov 2020 |
122 |
| 15 |
Wheat Yield Forecasting for Punjab Province from Vegetation Index Time Series and Historic Crop Statistics
Jan Dempewolf, Bernard Adusei, Inbal Becker‐Reshef et al. · Remote Sensing
Open access |
13 Oct 2014 |
120 |
| 16 |
Validity judgments of rumors heard multiple times: the shape of the truth effect
Nicholas DiFonzo, Jason W. Beckstead, Noah Stupak et al. · Social Influence
Open access |
2 Jan 2016 |
114 |
| 17 |
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
Aditya Bardia, Virginia Kaklamani, Sharon T. Wilks et al. · Journal of Clinical Oncology
Open access |
29 Jan 2021 |
111 |
| 18 |
Use of Bone Health Evaluation in Orthopedic Surgery: 2019 ISCD Official Position
Paul A. Anderson, Sarah Morgan, Diane C. Krueger et al. · Journal of Clinical Densitometry
|
16 Aug 2019 |
99 |
| 19 |
Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1–34)
Jacquelin Jolette, Bassem Attalla, Aurore Varela et al. · Regulatory Toxicology and Pharmacology
Open access |
4 Apr 2017 |
96 |
| 20 |
Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors
Felicia Cosman, Gary Hattersley, Ming‐yi Hu et al. · Journal of Bone and Mineral Research
Open access |
9 Sep 2016 |
93 |
| 21 |
Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults
Dorene M. Rentz, Kathryn V. Papp, Danielle V. Mayblyum et al. · Neurology
Open access |
5 Apr 2021 |
85 |
| 22 |
Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial
Carolina Aguiar Moreira, Lorraine A. Fitzpatrick, Yamei Wang et al. · Bone
Open access |
5 Nov 2016 |
81 |
| 23 |
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
Hitisha Patel, Nianjun Tao, Kyung-Min Lee et al. · Breast Cancer Research
Open access |
Dec 2019 |
79 |
| 24 |
One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption
Aurore Varela, Luc Chouinard, Elisabeth Lesage et al. · Journal of Bone and Mineral Research
Open access |
17 Oct 2016 |
75 |
| 25 |
Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption
Nicole Doyle, Aurore Varela, Samuel S. Haile et al. · Osteoporosis International
Open access |
19 Dec 2017 |
74 |
| 26 |
Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f®): long-term treatment in azoospermic men with hypogonadotropic hypogonadism
Alvin M. Matsumoto, Peter J. Snyder, Shalender Bhasin et al. · Fertility and Sterility
Open access |
19 Oct 2008 |
72 |
| 27 |
Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140
Chris P. Miller, Maysoun Shomali, C. Richard Lyttle et al. · ACS Medicinal Chemistry Letters
Open access |
2 Dec 2010 |
72 |
| 28 |
EMERALD: Phase III Trial of Elacestrant (RAD1901) vs Endocrine Therapy for Previously Treated ER+ Advanced Breast Cancer
Aditya Bardia, Philippe Georges Aftimos, Teeru Bihani et al. · Future Oncology
Open access |
20 Aug 2019 |
70 |
| 29 |
Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, double‐blind, placebo‐controlled, proof‐of‐efficacy study
Zeev Shoham, Harold C. Smith, Timothy R. Yeko et al. · Clinical Endocrinology
|
14 May 2008 |
70 |
| 30 |
Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project
Richard Eastell, Eric Vittinghoff, Li‐Yung Lui et al. · Journal of Bone and Mineral Research
Open access |
Dec 2020 |
68 |
| 31 |
Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial
John Paul Bilezikian, Gary Hattersley, Lorraine A. Fitzpatrick et al. · Osteoporosis International
Open access |
22 Nov 2017 |
67 |
| 32 |
Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial
Paul D. Miller, Gary Hattersley, Esther Yuet Ying Lau et al. · Bone
Open access |
22 Oct 2018 |
66 |
| 33 |
Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
Vibeke Strand, Paul Miller, Setareh A. Williams et al. · Rheumatology and Therapy
Open access |
22 Aug 2017 |
66 |
| 34 |
Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect
Louis St L O'Dea, Fanny O’Brien, Karen Currie et al. · Current Medical Research and Opinion
|
25 Aug 2008 |
65 |
| 35 |
Challenges in osteoporosis awareness and management: results from a survey of US postmenopausal women
E. Michael Lewiecki, Deane Leader, RICHARD J. WEISS et al. · Journal of Drug Assessment
Open access |
2019 |
61 |
| 36 |
Characterizing Congo Basin Rainfall and Climate Using Tropical Rainfall Measuring Mission (TRMM) Satellite Data and Limited Rain Gauge Ground Observations
Yolande A. Munzimi, Matthew C. Hansen, Bernard Adusei et al. · Journal of Applied Meteorology and Climatology
|
31 Dec 2014 |
59 |
| 37 |
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
Benjamin Z. Leder, Bruce Mitlak, Ming‐yi Hu et al. · The Journal of Clinical Endocrinology & Metabolism
Open access |
Nov 2019 |
58 |
| 38 |
Impact of fractures on quality of life in patients with osteoporosis: a US cross-sectional survey
Deborah T. Gold, Setareh A. Williams, RICHARD J. WEISS et al. · Journal of Drug Assessment
Open access |
2019 |
58 |
| 39 |
Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss
Man‐Hai Liu, Pam Kurimoto, J. Zhang et al. · Journal of Dental Research
|
4 Apr 2018 |
57 |
| 40 |
Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
Ruban Dhaliwal, Didier B. Hans, Gary Hattersley et al. · JBMR Plus
Open access |
30 Jan 2020 |
54 |
| 41 |
Ethical Considerations in the Development and Deployment of AI Systems
Bhargav Kumar Konidena, Jesu Narkarunai Arasu Malaiyappan, Anish Tadimarri · European Journal of Technology
Open access |
26 Mar 2024 |
52 |
| 42 |
Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017
E. Michael Lewiecki, Benjamin J. Chastek, Kevin J. Sundquist et al. · Osteoporosis International
Open access |
15 Feb 2020 |
52 |
| 43 |
The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study
Eugene Vincent McCloskey, Helena Johansson, Anders Odén et al. · Journal of Bone and Mineral Research
Open access |
5 May 2017 |
52 |
| 44 |
One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats
Aurore Varela, Luc Chouinard, Elisabeth Lesage et al. · Bone
Open access |
25 Nov 2016 |
52 |
| 45 |
Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
Richard Eastell, Bruce Mitlak, Yamei Wang et al. · Osteoporosis International
Open access |
11 Jan 2019 |
51 |
| 46 |
Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis
J.-Y. Reginster, F. Bianic, Ross Campbell et al. · Osteoporosis International
Open access |
6 Apr 2019 |
51 |
| 47 |
Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study
Felicia Cosman, Cyrus Cooper, Yamei Wang et al. · Osteoporosis International
Open access |
7 May 2022 |
50 |
| 48 |
Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling
Renaud Winzenrieth, Michael S. Ominsky, Yamei Wang et al. · Osteoporosis International
Open access |
26 Jan 2021 |
50 |
| 49 |
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging
Agnes Jager, Elisabeth G.E. de Vries, C. Willemien Menke‐van der Houven van Oordt et al. · Breast Cancer Research
Open access |
11 Sep 2020 |
50 |
| 50 |
Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial
John Paul Bilezikian, Gary Hattersley, Bruce Mitlak et al. · Current Medical Research and Opinion
Open access |
16 Aug 2019 |
50 |